AVPR2 and autosomal dominant polycystic kidney disease: The second was a pharmacological approach using the administration to jck mice of either TUDCA, which resolves ER stress and restores proteostasis, or tolvaptan, an AVPR2 antagonist and the only approved therapy for ADPKD.